A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults.
Thirty-seven adult patients meeting the Utah criteria for attention deficit disorder, residual type, were entered into a double-blind crossover trial of methylphenidate and placebo. A moderate-to-marked therapeutic response occurred in 21 (57%) of the patients while receiving methylphenidate and in four (11%) while receiving placebo, a highly significant difference statistically and clinically. The responding patients showed significant improvement in the following areas: attentional difficulty, motor overactivity, affective lability, and impulsivity. The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability, and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders.
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001883:Borderline Personality Disorder / Q000175:diagnosis; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D019964:Mood Disorders / Q000175:diagnosis / Q000523:psychology; D010043:Outcome and Process Assessment, Health Care; D010555:Personality Inventory; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012569:Schizotypal Personality Disorder / Q000175:diagnosis
D010919:Placebos; D008774:Methylphenidate